PRIME MEMBER EXCLUSIVE | 3 Months Free Trial

Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.

FDA committee unanimously recommends first mRNA flu vaccine — 2026-06-19

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

FDA committee unanimously recommends first mRNA flu vaccine — 2026-06-19

Listen for free

View show details

## Short Segments ## Feature Story In a unanimous decision, the FDA's top vaccine advisory committee has recommended the approval of the first mRNA-based flu vaccine, marking a significant milestone in influenza prevention. The vaccine, developed by Moderna and branded as mFlusiva, is designed for adults aged 50 and over. This recommendation is a pivotal step towards introducing a new tool in the fight against influenza, leveraging the same mRNA technology that was instrumental in the COVID-19 pandemic response. The advisory committee, known as the Vaccines and Related Biological Products Advisory Committee (VRBPAC), voted 9-0 in favor of the vaccine. This marks the first time since 2023 that the committee has reviewed a new vaccine application, highlighting the significance of this development. Moderna's mRNA flu vaccine, mRNA-1010, demonstrated approximately 27% greater efficacy compared to standard flu shots in late-stage trials. This increased effectiveness could provide a more robust defense against seasonal influenza, particularly for older adults who are at higher risk of severe illness. While the unanimous endorsement by the advisory panel is a strong indicator of the vaccine's potential, questions remain about its availability to the public. The FDA will now consider the committee's recommendation as it evaluates the vaccine for full approval for those aged 50 to 64, and accelerated approval for those 65 and older. The introduction of an mRNA flu vaccine could revolutionize how influenza is managed, offering a more adaptable and potentially more effective option for public health officials. This technology allows for quicker updates to the vaccine's formulation, which could be crucial in responding to rapidly evolving flu strains. As the FDA deliberates on the final approval, the potential impact of mFlusiva on public health remains a key focus. If approved, it would be the world's first mRNA flu shot, setting a precedent for future vaccine developments. Listeners should stay tuned for further updates as the FDA's decision will determine the next steps in making this innovative vaccine available to the public. The outcome could significantly influence flu vaccination strategies in the coming years.

No reviews yet